Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005855 · ClinicalTrials.gov registry record · Phase 1
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
A Phase 1 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00005855 is a Phase 1 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium. The registered enrollment target is 48 participants.
The verdict
NCT00005855, a Phase 1 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of efaproxiral when given with carmustine and to see how well they work in treating patients with progressive or recurrent malignant glioma.
Interventions
- DRUG carmustine
- DRUG efaproxiral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2000-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005855
The ClinicalTrials.gov registry entry for NCT00005855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carmustine is the first listed.
NCT00005855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005855 about?
NCT00005855 is a clinical study titled "Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of efaproxiral when given with carmustine and to ...
What is the current status of trial NCT00005855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2000-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00005855?
The interventions under investigation include: carmustine (DRUG), efaproxiral (DRUG).
Who is sponsoring clinical trial NCT00005855?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.